published meta-analysis   sensitivity analysis   studies

metformin in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsCOVID-OUT (metformin), 2022 0.58 [0.35; 0.95] 0.58[0.35; 0.95]COVID-OUT (metformin), 202210%1,307NAnot evaluable hospitalization or deathdetailed resultsCOVID-OUT (metformin), 2022 0.47 [0.20; 1.11] 0.47[0.20; 1.11]COVID-OUT (metformin), 202210%1,307NAnot evaluable clinical deteriorationdetailed resultsCOVID-OUT (metformin), 2022 0.84 [0.65; 1.08] 0.84[0.65; 1.08]COVID-OUT (metformin), 202210%1,305NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-25 16:32 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 699 - roots T: 290